Emilia J. Diego

Oct 17, 2024 | digitalcommons.library.tmc.edu | Helen Johnson |Heather Lin |Yu Shen |Emilia J. Diego

IMPORTANCE: Patients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials. OBJECTIVE: To evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfort and health-related quality of life (HRQOL) among patients who elected to enroll in a clinical trial evaluating radiotherapy alone, without breast surgery, for invasive breast cancers with exceptional response to neoadjuvant systemic therapy (NST).

Sep 14, 2023 | jamanetwork.com | Helen Johnson |Heather Y. Lin |Yu Shen |Emilia J. Diego

Key PointsQuestion  How do patients describe their experiences participating in a clinical trial evaluating omission of breast surgery for invasive cancers with exceptional response to neoadjuvant systemic therapy? Findings  In this nonrandomized phase 2 clinical trial of 31 patients, decisional comfort and health-related qualify of life (HRQOL) were high at baseline and increased significantly during postradiotherapy surveillance (median follow-up 32.4 months).